Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC - BeOne

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

BeOne Study ID

BGB-A317-301

ClinicalTrials.gov ID

NCT03412773

EudraCT Number

2017-002423-19

China Drug Trials ID

CTR20170882

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary

Study Overview

Sex: All

Age: 18 Years / N/A

Accepts Healthy Volunteers? yes

Study Documents

Plain Language Summary